Biosergen AB (SE:BIOSGN)
:BIOSGN
Want to see SE:BIOSGN full AI Analyst Report?
BIOSGN Stock Chart & Stats
kr42.60
<kr0.01(1.20%)
At close: 4:00 PM EST
kr42.60
<kr0.01(1.20%)
Day’s Range― - ―
52-Week Rangekr9.45 - kr67.80
Previous CloseN/A
Volume13.64K
Average Volume (3M)126.26K
Market Cap
kr23.72M
Enterprise Value-kr9.55M
Total Cash (Recent Filing)kr33.27M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-1.03
Next Earnings
May 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.31
Shares Outstanding2,348,232
10 Day Avg. Volume207,862
30 Day Avg. Volume126,261
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.64
Price to Sales (P/S)0.00
P/FCF Ratio-7.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10
Revenue Forecast (FY)kr1.40M
Bulls Say, Bears Say
Bulls Say
Targeted Antifungal PipelineBiosergen’s focus on BSG005 for invasive fungal infections addresses a structural unmet need in hospital and critical‑care settings where resistance and toxicity limit options. A successful clinical/regulatory outcome would create a durable franchise in a niche with high clinical importance and limited competition.
Debt‑free Balance SheetHaving no reported debt and stronger equity reduces bankruptcy and interest risk, preserving strategic flexibility. This structural financial strength lengthens runway for R&D or partnership negotiations and reduces fixed obligations that could otherwise constrain long‑term drug development efforts.
Improving Cash Burn TrendA materially lower cash burn in 2024 shows better cost control or milestone progress, improving runway and reducing near‑term funding needs. Sustained improvement increases probability of reaching clinical inflection points without immediate dilutive raises, a positive structural trend for a pre‑revenue biotech.
Bears Say
Pre‑revenue With Ongoing LossesThe absence of recurring revenue and persistent sizeable net losses mean the company must continually access capital to fund operations. This structural dependence on external financing increases dilution risk and leaves long‑term viability contingent on successful clinical or partnering outcomes rather than operating cash generation.
Negative Returns And Equity RelianceMeaningfully negative ROE and reliance on equity funding indicate the business is not generating investor returns from operations. Over the medium term this creates vulnerability to capital market conditions, potential dilution from raises, and constrained strategic choices if funding environments tighten.
Very Small Operating TeamWith only two employees the company has limited internal capacity to run complex clinical programs, regulatory activity, or commercialization prep. This reliance on external CROs and partners raises execution risk, potential coordination delays, and reduces operational resilience over the medium term.
Biosergen AB News
BIOSGN FAQ
What was Biosergen AB’s price range in the past 12 months?
Biosergen AB lowest stock price was kr9.45 and its highest was kr67.80 in the past 12 months.
What is Biosergen AB’s market cap?
Biosergen AB’s market cap is kr23.72M.
When is Biosergen AB’s upcoming earnings report date?
Biosergen AB’s upcoming earnings report date is May 28, 2026 which is in 27 days.
How were Biosergen AB’s earnings last quarter?
Biosergen AB released its earnings results on Mar 27, 2026. The company reported -kr5.307 earnings per share for the quarter, missing the consensus estimate of N/A by -kr5.307.
Is Biosergen AB overvalued?
According to Wall Street analysts Biosergen AB’s price is currently Overvalued.
Does Biosergen AB pay dividends?
Biosergen AB does not currently pay dividends.
What is Biosergen AB’s EPS estimate?
Biosergen AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosergen AB have?
Biosergen AB has 2,348,232 shares outstanding.
What happened to Biosergen AB’s price movement after its last earnings report?
Biosergen AB reported an EPS of -kr5.307 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.549%.
Which hedge fund is a major shareholder of Biosergen AB?
Currently, no hedge funds are holding shares in SE:BIOSGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biosergen AB
Biosergen AB, a biopharmaceutical company, engages in the development of antifungal products. It is developing BSG005, an antifungal drug candidate for the treatment of life threatening invasive fungal diseases. The company was founded in 2004 and is headquartered in Solna, Sweden.
Technical Analysis
Alzinova AB
―
Nanologica AB
―
Lipigon Pharmaceuticals AB
―
NextCell Pharma AB
―
Spago Nanomedical AB
―